Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer

  • Authors:
    • Shi Luo
    • Chubo Xie
    • Ping Wu
    • Jian He
    • Yaoyun Tang
    • Jing Xu
    • Suping Zhao
  • View Affiliations

  • Published online on: October 12, 2017     https://doi.org/10.3892/etm.2017.5298
  • Pages:6113-6118
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Due to the lack of a definite diagnosis, a frequent recurrence rate and resistance to chemotherapy or radiotherapy, the clinical outcome for patients with advanced laryngeal cancer has not improved over the last decade. Annexin A2 is associated with the invasion and metastasis of cancer cells. In the present study, it was demonstrated using differential proteomics analysis that Annexin A2 is highly expressed in laryngeal carcinoma tissues and this was confirmed using immunohistochemistry, which demonstrated that the expression of Annexin A2 in laryngeal carcinoma tissues was significantly higher than in healthy adjacent tissue. In addition, its potential predictive value in the prognosis of patients with laryngeal carcinoma was evaluated. The results demonstrated that Annexin A2 expression was significantly associated with tumor size, lymph node metastasis, distant metastasis and clinical stage. In addition, higher Annexin A2 expression was associated with a poor prognosis of patients with laryngeal cancer. Thus, the results of the present study indicate that Annexin A2 expression is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Luo, S., Xie, C., Wu, P., He, J., Tang, Y., Xu, J., & Zhao, S. (2017). Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer. Experimental and Therapeutic Medicine, 14, 6113-6118. https://doi.org/10.3892/etm.2017.5298
MLA
Luo, S., Xie, C., Wu, P., He, J., Tang, Y., Xu, J., Zhao, S."Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer". Experimental and Therapeutic Medicine 14.6 (2017): 6113-6118.
Chicago
Luo, S., Xie, C., Wu, P., He, J., Tang, Y., Xu, J., Zhao, S."Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer". Experimental and Therapeutic Medicine 14, no. 6 (2017): 6113-6118. https://doi.org/10.3892/etm.2017.5298